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Predictors of Biologic Use and Satisfaction
Among Patients With Psoriasis: An Analysis
and Geographic Visualization of the 2016
and 2017 National Psoriasis Foundation
Annual Surveys
Clinton W. Enos, MD1 , Hadiza Galadima, PhD2 ,
Arjun D. Saini, MD3 , Stacie Bell, PhD4, Michael Siegel, PhD5,
and Abby S. Van Voorhees, MD1
Abstract
Background: There are an increasing number of biologic therapies approved for the treatment of psoriasis. Previous reports
have identified undertreatment as a concern in the United States. Undertreatment has been associated with decreased patient
satisfaction and increased morbidity. Objectives: Assess biologic use and satisfaction among respondents to the 2016 and 2017
National Psoriasis Foundation (NPF) Annual Surveys. Methods: Retrospective data analysis of the 2016 and 2017 NPF Annual
Survey responses from individuals with psoriasis. ArcGIS Pro software was utilized to generate maps and perform an optimized
hot spot analysis of moderate-to-severe psoriasis and biologic use. Results: There were 427 patients with psoriasis involving the
skin alone. Biologics were used in <23% of respondents, while nearly 69% reported body surface area (BSA) >3%. Respondents
with BSA <3% and 3% to 4% were less likely to be on biologic therapy (odds ratio [OR]: 0.29, 0.11-0.78 and OR: 0.22, 0.09-0.56,
respectively). Nonbiologic users were more likely to be very unsatisfied with their treatment compared to those receiving
biologic therapy (OR: 5.23, 2.80-9.75). With geographic information systems (GIS), counties with increased moderate-to-severe
disease were identified in the southeastern United States. Conclusion: Despite the increasing number of Food and Drug
Administration–approved biologic medications, the proportion of respondents on biologic therapy remained small. Treatment
with biologics correlated with less residual disease and increased satisfaction. Geographic variation in state legislation as well as
state and federal health insurance did not impact biologic use. However, using GIS, we identify a greater burden of moderate-to-
severe disease among respondents in the Southeastern United States and a lack of commensurate use of biologics in those areas.
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Background
Psoriasis is a chronic, immune-mediated, inflammatory disease
affecting roughly 3% of the US population.1 Traditionally,
psoriasis has been described as a disease of the skin and joints;
however, it is now understood to have a systemic impact. Sub-
sequently, treating to the target of a body surface area (BSA)
1% within 3 months of starting therapy has been proposed as
a primary focus.2
The past decade has brought multiple additions to the arma-
mentarium for psoriatic disease. Among these, the biologics
have revolutionized both our understanding of psoriasis and
the potential for achieving treatment goals in moderate-to-
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severe psoriasis; further, their benefit-to-risk profile has been
very positive.3 At time of writing, there are 12 Food and Drug
Administration–approved biologic therapies (not including
biosimilars) for the treatment of psoriatic disease. Despite this,
undertreatment and dissatisfaction with treatment are signifi-
cant problems in the United States.4
The National Psoriasis Foundation (NPF) conducts an
annual survey that targets a patient population with
moderate-to-severe disease and collects data on self-reported
BSA, treatment history, demographic information, as well as
satisfaction. Here we (1) characterize the respondent popula-
tion of the 2016 and 2017 NPF Annual Surveys stratified by
treatment with biologics, (2) assess treatment satisfaction
among individuals with psoriasis, and (3) use geographic infor-
mation systems (GIS) to analyze potential spatial differences in
biologic use. We hypothesized that (1) a majority of respon-
dents would be treated with biologics, (2) respondents receiv-
ing biologic therapy would be more satisfied with their
treatment, and (3) the use of biologics is impacted by geo-
graphic differences in state legislation as well as federal and
state health insurance expansion.
Methods and Design
The study was approved by the Eastern Virginia Medical
School institutional review board (18-03-NH-0069-EVMS).
The NPF collects data as part of an annual survey conducted
via email and telephone. The 2016 and 2017 annual surveys
were used in this analysis. The survey asks respondents to self-
report severity using BSA where one hand is equivalent to 1%
BSA. Data are also collected on demographics, treatment(s)
used, satisfaction with treatment, impact on daily life, specialty
of provider caring for their psoriatic disease, barriers to treat-
ment, and comorbidities. Respondents identifying as having
psoriatic arthritis were excluded from the analysis. Treatments
were categorized as biologic or nonbiologic. Biologic treat-
ments listed in the 2016 and 2017 surveys included etanercept,
infliximab, adalimumab, golimumab, certolizumab, ustekinu-
mab, secukinumab, ixekinumab, brodalumab, guselkumab, and
infliximab-dyyb. Nonbiologic treatments included cyclospor-
ine, methotrexate, acitretin, apremilast, ultraviolet B photother-
apy, excimer, pulse dye laser, nonsteroidal topical medications,
and topical steroids.
Satisfaction was a primary outcome measure. The survey
included a question on satisfaction with treatment, and each
response was measured on a scale of 10 ranging from very
unsatisfied (1) to very satisfied (10). The response variable was
regrouped into 4 categories to allow for larger numbers in each
and create a new ordinally scaled response variable to measure
satisfaction such that 1 ¼ very unsatisfied, between 2 and 5 ¼
unsatisfied, between 6 and 9 ¼ satisfied, and 10 ¼ very
satisfied.
The primary independent variables included a binary vari-
able representing whether a patient received biologic therapy
(“biologic”), and a current disease severity variable recorded
on 6 scales (1 ¼ “no or very little psoriasis,” 2 ¼ “<3% BSA,”
3 ¼ “3% to 4% BSA,” 4 ¼ “5% to 10% BSA,” 5 ¼ “11% to
20% BSA,” and 6 ¼ “>20% BSA”). We also evaluated demo-
graphic covariates that included age, sex, race/ethnicity,
household income, insurance provider, and total number of
comorbidities. A quality of life variable measuring psoriasis
impact was also included; this information is collected on a
scale of 1 to 10 (10 being a “very large problem” and 1 being
“no problem at all”) and was considered a continuous variable
for the analysis.
Geographic variables chosen for the analysis included: resi-
dence in a Medicaid expansion state, residence in a state with
Step therapy legislation, residence within 50 or 100 miles of an
active NPF medical board member. States with Medicaid
expansion at time of writing are Alaska, Arkansas, Arizona,
California, Colorado, Connecticut, District of Columbia, Dela-
ware, Hawaii, Iowa, Idaho, Illinois, Indiana, Kentucky, Louisi-
ana, Massachusetts, Maryland, Maine, Michigan, Minnesota,
North Dakota, Nebraska, North Hampshire, New Jersey, New
Mexico, Nevada, New York, Ohio, Oregon, Pennsylvania,
Utah, Virginia, Vermont, Washington, and West Virginia.5
States with Step therapy legislation enacted at time of writing
are Oregon, California, New Mexico, Texas, Kansas, Missouri,
Arkansas, Louisiana, Mississippi, Illinois, Kentucky, Indiana,
West Virginia, and New York.6 Geographic region (census
division and census region) was also considered a covariate
of interest to see if the correlation between satisfaction, biolo-
gics use, and disease severity is different according to the geo-
graphic location.
Statistical Analysis
Baseline demographics, clinical, and geographic characteris-
tics were summarized and compared between those who used
biologics and those who did not in a bivariate analysis using the
w2 test for categorical variables and the Student t test for con-
tinuous variables. A multivariable logistic regression adjusting
for age, sex, ethnicity, income, insurance, the geographic vari-
ables, and the provider specialty was used to model the odds of
biologics use. Adjusted odds ratios with their 95% confidence
intervals (CIs) were reported.
Analysis of variance, Chi-square, and Fisher exact tests
were used in a univariate analysis to compare baseline clinical
and demographic patient characteristics by satisfaction cate-
gory. A cumulative logit model was used to investigate the
effects of biologic therapy and disease severity on satisfaction
while adjusting for the significant covariates found in the uni-
variate analysis. The model also included an interaction term
between biologic and disease severity to examine the potential
differences of biologic use within each level of severe psoria-
sis. Bonferroni method for multiple comparisons was used to
identify significant differences. The model yielded adjusted
odds ratios with their 95% CIs. All analyses were performed
using SAS version 9.4 (SAS Institute) and the statistical sig-
nificance level was set at a ¼ .05.
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Map Generation
ArcGIS Pro (Esri) was used to generate maps by linking survey
responses to zip codes. Responses were summarized into coun-
ties. The optimized Hot Spot analysis tool was used to identify
counties with significant clustering of respondents with
moderate-to-severe psoriasis and biologic use among
moderate-to-severe psoriasis; counts normalized to million
population per county were used for the hot spot analysis.
Table 1. Descriptive Statistics by Biologics Use.
Characteristics
Biologics (no) Biologics (yes)
P value
All patients
n ¼ 330 (77.28%) n ¼ 97 (22.72%) N ¼ 427 (100%)
Demographics and disease characteristics
Age, mean (SD) 56.90 (15.64) 53.68 (15.63) .0756 56.16 (15.67)
Gender, n (%)
Female 187 (56.67) 60 (61.86) .3629 247 (57.85)
Male 143 (43.33) 37 (38.14) 180 (42.15)
Ethnicity, n (%)
African American 10 (3.05) 2 (2.08) .5648 12 (2.83)
Asian American 8 (2.44) 0 (0.00) 8 (1.89)
Caucasian 274 (83.54) 85 (88.54) 359 (84.67)
Hispanic, Latino, or of Spanish origin 10 (3.04) 4 (4.16) 14 (3.30)
Mixed race 5 (1.52) 3 (3.13) 8 (1.89)
Native American 3 (0.91) 0 (0.00) 3 (0.71)
Other 10 (3.05) 1 (1.04) 11 (2.59)
Pacific Islander 1 (0.30) 0 (0.00) 1 (0.24)
Refused 5 (1.52) 0 (0.00) 5 (1.18)
Unsure 2 (0.61) 1 (1.04) 3 (0.71)
Household income, US$, n (%)
<15 000 11 (3.33) 3 (3.09) .0314 14 (3.28)
15 000-<30 000 30 (9.09) 14 (14.43) 44 (10.3)
30 000-<50 000 51 (15.45) 17 (17.53) 68 (15.93)
50 000-<75 000 53 (6.06) 13 (13.40) 66 (15.46)
75 000-<100 000 36 (10.91) 20 (20.62) 56 (13.11)
>100 000 88 (26.67) 24 (24.74) 112 (26.23)
Refused 53 (16.06) 5 (5.15) 58 (13.58)
Unsure 8 (2.42) 1 (1.03) 9 (2.11)
Insurance provider, n (%)
Third party 86 (26.14) 31 (31.96) .0714 117 (27.46)
Medicaid 16 (4.86) 4 (4.12) 20 (4.69)
Medicare 96 (29.18) 21 (21.65) 117 (27.46)
None 12 (3.65) 1 (1.03) 13 (3.05)
Refused 6 (1.82) 0 (0.00) 6 (1.41)
Unsure 11 (3.34) 0 (0.00) 11 (2.58)
Severity, n (%)
No or very little psoriasis 35 (10.61) 20 (20.62) .0084 55 (12.88)
<3% BSA 68 (20.61) 10 (10.31) 78 (18.27)
3%-4% BSA 81 (24.55) 16 (16.49) 97 (22.72)
5%-10% BSA 86 (26.06) 29 (29.90) 115 (26.93)
11%-20% BSA 40 (12.12) 18 (18.56) 58 (13.58)
>20% BSA 20 (6.06) 4 (4.12) 24 (5.62)
Specialty of provider, n (%)
Dermatologist 214 (64.85) 89 (91.75) .0001 303 (70.96)
General or family practitioner 27 (8.18) 3 (3.09) 30 (7.03)
General physician assistant 4 (1.21) 1 (1.03) 5 (1.17)
Internist 5 (1.52) 0 (0.00) 5 (1.17)
Not currently seeing a doctor 48 (14.55) 0 (0.00) 48 (11.24)
Nurse practitioner 6 (1.82) 0 (0.00) 6 (1.41)
Other service provider 2 (0.61) 1 (1.03) 3 (0.7)
Primary care doctor 19 (5.76) 1 (1.03) 20 (4.68)
Rheumatologist 5 (1.52) 2 (2.06) 7 (1.64)
Abbreviations: BSA, body surface area; SD, standard deviation.
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Results
Respondent Characteristics
There were a combined 826 respondents to the 2016 and 2017
NPF Annual Surveys; of these, 427 did not report joint disease
and were included in the study (Table 1). The average age was
56.1 (standard deviation [SD]¼ 15.6) years and about 84% (n¼
359) identified as Caucasian. The majority of respondents were
female (57.8%, n ¼ 247) and about 26% (n ¼ 112) had an
income of more than US$100 000. Roughly, 27% (n ¼ 117)
utilized private insurance from a third party; a similar proportion
used Medicare (27%, n¼ 117); Medicaid was used in <5%; and
around 3% of respondents lacked health insurance. Nearly 69%
of respondents reported BSA >3%, with the greatest proportion
being BSA 5% to 10% (26.9%, n ¼ 115). The majority of
respondents were managed by a dermatologist (71%, n ¼
303); and there was no significant evidence of association
between disease severity and specialty of provider (P ¼ .387).
Biologic Use Among Respondents
Less than one-quarter of respondents (22.7%, n ¼ 97) were
treated with biologics (Table 1). Of those receiving biologics,
the most frequent responses included income more than
US$100 000 (n ¼ 24, 24.7%), use of a third-party medical
insurance (n ¼ 31, 31.9%), managed by a dermatologist (n ¼
81, 91.7%), and BSA of 5% to 10% (n ¼ 29, 29.9%; Table 1).
In the univariate analysis, income level (US$15 000-US$100
000) favored use of biologics (P ¼ .031); however, this rela-
tionship was lost in the multivariate analysis. For each level of
disease severity, respondents more frequently reported not
being on a biologic (P ¼ .008; Supplementary Table 1). In the
multivariate analysis, patients with BSA < 3% and BSA 3% to
4% had a lower odds of being on biologic therapy compared to
those responding as having “no or very little psoriasis” (71%
and 78% lower odds, 95% CI, 0.11-0.78 and 95% CI, 0.09-0.56,
respectively; Table 2). Respondents managed by a dermatolo-
gist were more frequently treated with biologics (91.7% vs
64.8%, P ¼ .0001; Table 1). When respondents were managed
by a provider other than a dermatologist, they were less likely
to be on a biologic: for example, there was roughly a 92%
lower likelihood of being on a biologic if managed by a nurse
practitioner (95% CI, 0.01-0.50) and 83% lower if managed by
a primary care doctor (95% CI, 0.03-0.92; Table 2).
Patient Satisfaction Is Greater When Biologics Are Used
in the Treatment of Psoriasis
Of the 427 respondents, 22 were missing satisfaction survey
responses and excluded from the analyses. Overall, the major-
ity of respondents reported being either “satisfied” (n ¼ 199,
49.1%) or “unsatisfied” (n ¼ 109, 26.9%) with treatment; the
least (n ¼ 23, 5.6%) reported being “very unsatisfied” and n ¼
74 (18.2%) were “very satisfied” with treatment (Table 3).
Among patients on biologic (n ¼ 94), about 87% (n ¼ 82)
reported being either satisfied or very satisfied with treatment
versus roughly 13% (n ¼ 12) with lesser satisfaction (P <
.0001). Respondents “very satisfied” with treatment more often
had little to no psoriasis (n ¼ 22, 29.7%), utilized private (third
party) insurance (n ¼ 39, 52.7%), reported >US$100 000
annual income (n ¼ 20, 27%), and reported one comorbid
disease (n ¼ 20, 27.0%). Very satisfied respondents also
reported a lower mean impact on quality of life (3.58) com-
pared to all other levels of satisfaction (P ¼ .0178). Whereas
respondents “very unsatisfied” with treatment more often had
BSA 3% to 4% (n ¼ 6, 26%), utilized Medicare (n ¼ 12;
52.1%), reported annual income US$30 000 to US$50 000 (n
¼ 8, 34.7%), and reported no comorbid disease (n¼ 8, 34.7%).
Very unsatisfied respondents reported the greatest impact on
quality of life (6.32; Table 3).
After adjusting for household income, insurance status, total
comorbidities, disease severity, biologic use, and psoriasis
impact on quality of life, predictors of being very unsatisfied
were determined (Table 4). Nonbiologic users were roughly 5
times more likely to be very unsatisfied with their treatment
compared to those receiving biologic (95% CI, 2.80-9.75).
Respondents with BSA ranging 3% to 20% were roughly 2 to
5 times more likely to be very unsatisfied with their treatment,
when compared to having no or very little psoriasis (P ¼
.0008). At all levels of severity, there was a greater probability
of being unsatisfied or very unsatisfied when not treated with a
biologic compared to those treated with a biologic (P ¼ .0401;
Figure 1). Compared to those with a private insurance, Medi-
care recipients were 1.75 times more likely to be very unsatis-
fied with their treatment (95% CI, 1.06-2.88); the uninsured
were 5 times more likely to be very unsatisfied with treatment
(95% CI, 1.74-19.4). Lastly, patients reporting greater impact
on quality of life were 1.18 times more likely to be very unsa-
tisfied with treatment (95% CI, 1.09-1.27).
Table 2. Predictors of Biologic Use Among Respondents of the 2016






Specialty of provider (reference:
dermatologist)
P ¼ .001
Family/nurse practitioner or general 0.08 0.01 0.50
General physician assistant/doctor of
internal medicine
0.28 0.04 1.97
Not currently seeing a doctor or other 0.07 0.02 0.36
Primary care doctor 0.17 0.03 0.92
Rheumatologist 0.75 0.11 5.25
Severity (reference: no or very little
psoriasis)
P ¼ .0233
<3% BSA 0.29 0.11 0.78
3%-4% BSA 0.22 0.09 0.56
5%-10% BSA 0.49 0.21 1.14
11%-20% BSA 0.65 0.24 1.79
>20% BSA 0.46 0.11 1.88
Abbreviation: BSA, body surface area.
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Geographic Variables and Biologic Use
Next we sought to understand if geographic variations in leg-
islation (Step therapy legislation), health insurance (Medicaid
expansion), or proximity to a psoriasis thought leader might
impact biologic use among survey respondents (Supplemental
Table 2). Neither Medicaid expansion nor Step therapy legis-
lation was associated with biologic use. Biologics were more
frequently used when respondents resided within 100 miles of
an NPF medical board member (P ¼ .0161); however, this
relationship was lost in the multivariate analysis (data not
shown). There was also no evidence that satisfaction with treat-
ment varied regionally (P¼ .0687 for US census division and P
¼ .138 for US census region, data not shown).
Geographic Clustering of Moderate-to-Severe Psoriasis
and Biologic Use
Using GIS software, respondents were mapped by county to
show the spatial distribution of moderate-to-severe psoriasis
and biologic use (Figure 2A). An optimized hot spot analysis













18-34 1 (4.35%) 10 (9.17%) 22 (11.11%) 3 (4.05%) .0518 36 (8.88%)
35-49 3 (13.04%) 29 (26.61%) 56 (28.28%) 18 (24.32%) 106 (26.17%)
50-64 7 (30.43%) 35 (32.11%) 63 (31.82%) 16 (21.62%) 121 (29.87%)
65þ 12 (52.17%) 35 (32.11%) 57 (28.79%) 37 (50%) 141 (34.81%)
Sex
Female 16 (69.57%) 61 (55.96%) 119 (59.8%) 37 (50%) .3068 233 (57.53%)
Male 7 (30.43%) 48 (44.04%) 80 (40.2%) 37 (50%) 172 (42.46%)
Race/ethnicity
Caucasian 22 (95.65%) 87 (79.82%) 169 (84.92%) 63 (85.14%) .2649 341 (84.19%)
Non-Caucasian 1 (4.35%) 22 (20.18%) 30 (15.08%) 11 (14.86%) 64 (15.80%)
Household income, US$
<15 000 1 (4.35%) 6 (5.5%) 6 (3.02%) 0 (0%) .0278 13 (3.20%)
15 000-<30 000 4 (17.39%) 6 (5.5%) 21 (10.55%) 12 (16.22%) 43 (10.61%)
30 000-<50 000 8 (34.78%) 16 (14.68%) 29 (14.57%) 10 (13.51%) 63 (15.55%)
50 000-<75 000 3 (13.04%) 17 (15.6%) 32 (16.08%) 9 (12.16%) 61 (15.06%)
75 000-<100 000 0 (0%) 17 (15.6%) 25 (12.56%) 10 (13.51%) 52 (12.83%)
>100 000 7 (30.43%) 25 (22.94%) 59 (29.65%) 20 (27.03%) 111 (27.40%)
Refused/Unsure 0 (0%) 22 (20.18%) 27 (13.57%) 13 (17.561%) 62 (15.30%)
Insurance provider
Medicaid 0 (0%) 4 (3.7%) 9 (4.52%) 5 (6.76%) .0031 18 (4.44%)
Medicare 12 (52.17%) 32 (29.63%) 39 (19.6%) 28 (37.84%) 111 (27.40%)
None 2 (8.7%) 6 (5.56%) 4 (2.01%) 0 (0%) 12 (2.96%)
Private (third party) 9 (39.13%) 63 (58.33%) 137 (68.84%) 39 (52.7%) 248 (61.23%)
Refused/unsure 0 (0%) 3 (2.78%) 10 (5.03%) 2 (2.7%) 15 (3.70%)
Severity
No or very little psoriasis 3 (13.04%) 3 (2.75%) 23 (11.56%) 22 (29.73%) .0004 51 (12.59%)
<3% BSA 2 (8.7%) 18 (16.51%) 41 (20.6%) 15 (20.27%) 76 (18.76%)
3%-4% BSA 6 (26.09%) 28 (25.69%) 49 (24.62%) 10 (13.51%) 93 (22.96%)
5%-10% BSA 5 (21.74%) 33 (30.28%) 51 (25.63%) 18 (24.32%) 107 (26.41%)
11%-20% BSA 5 (21.74%) 22 (20.18%) 24 (12.06%) 5 (6.76%) 56 (13.82%)
>20% BSA 2 (8.7%) 5 (4.59%) 11 (5.53%) 4 (5.41%) 22 (5.43%)
Psoriasis impact on quality of life 6.32 (3.36) 5.59 (2.54) 5.38 (2.58) 3.58 (2.96) .0178
Total comorbidities
0 8 (34.78%) 44 (40.37%) 70 (35.18%) 14 (18.92%) .0256 136 (33.58%)
1 7 (30.43%) 25 (22.94%) 63 (31.66%) 20 (27.03%) 115 (28.39%)
2 1 (4.35%) 21 (19.27%) 27 (13.57%) 15 (20.27%) 64 (15.80%)
3 3 (13.04%) 13 (11.93%) 19 (9.55%) 11 (14.86%) 46 (11.35%)
4 4 (17.39%) 3 (2.75%) 14 (7.04%) 10 (13.51%) 31 (7.65%)
5þ 0 (0%) 3 (2.75%) 6 (3.02%) 4 (5.41%) 13 (3.20%)
Biologics
No 21 (91.3%) 99 (90.83%) 150 (75.38%) 41 (55.41%) <.0001 311 (76.79%)
Yes 2 (8.7%) 10 (9.17%) 49 (24.62%) 33 (44.59%) 94 (23.20%)
Abbreviation: BSA, body surface area.
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of respondents reporting moderate-to-severe psoriasis identi-
fied counties with statistically significant clustering with 90%
CIs in the southeastern region of the United States (Figure 2B).
Gating the input population to BSA  5% identified additional
counties in Texas and Florida and raised the CIs to 95% of
many of the previously identified counties in Tennessee, North
Carolina, South Carolina, Alabama, and Georgia (Figure 2C).
Similarly, counties with clustering of biologic use for the treat-
ment of moderate to severe psoriasis were identified in Texas,
Ohio, and Michigan with 90% and 95% CIs (Figure 2D).
Discussion
The treatment of psoriatic disease continues to evolve. Here we
specifically investigate biologic use among respondents to the
2016 and 2017 NPF Annual Surveys and assess satisfaction
with treatment. The NPF Annual Survey aims to assess multi-
ple variables from patients with moderate-to-severe psoriasis.
We show that despite the increasing numbers of biologic
therapies approved for the treatment of moderate-to-severe
psoriasis, the use was low (22.7%), opposing our initial hypoth-
esis. Nearly 69% of respondents reported psoriasis severity as
BSA  3%, indicating that undertreatment remains a concern
in an era of treatment targets.2 Further, the mild-to-moderate
disease severity group, those with BSA <3% and 3% to 4%,
were less likely to receive biologics compared to those with no
or very little psoriasis, highlighting an important patient demo-
graphic not receiving targeted therapy. The treatment of psor-
iasis has been pragmatically based on severity and therefore
may prohibit the use of biologics in individuals with more mild
disease.
Respondents were more satisfied with treatment when their
skin was clearer and were being treated with biologic therapy,
confirming our second hypothesis. Consistent with our results,
Table 4. Adjusted Odds Ratio of Being Very Unsatisfied With
Treatment.





No or very little psoriasis Reference .0008
<3% BSA 1.667 (0.688-4.036)
3%-4% BSA 3.534 (1.57-7.954)
5%-10% BSA 2.751 (1.321-5.732)
11%-20% BSA 5.334 (2.296-12.39)
>20% BSA 0.862 (0.215-3.457)
Household income, US$
<15 000 Reference .0542
15 000-<30 000 0.252 (0.073-0.872)
30 000-<50 000 0.856 (0.264-2.779)
50 000-<75 000 0.589 (0.179-1.933)
75 000-<100 000 0.641 (0.192-2.139)
>100 000 0.649 (0.206-2.041)
Refused/unsure 0.589 (0.177-1.964)
Insurance provider












Psoriasis impact 1.182 (1.095-1.275) <.0001
Abbreviation: BSA, body surface area.
Figure 1. Predicted probabilities for satisfaction. Predicted probabilities for satisfaction based on body surface area of psoriasis for those
treated with biologic and those not treated with biologic (P ¼ .0401).


















































































































































































































































































































































biologic treatment results in higher satisfaction scores when
compared to nonbiologic treatments (P < .001).7 Biologic use
lowers Dermatology Life Quality Index scores more than other
treatment modalities8; similarly, more severe disease has a
negative emotional and social impact on individuals with psor-
iasis.9 Concordant with these, we showed that a greater impact
of psoriasis on a respondent’s daily life was predictive of being
very unsatisfied with treatment.
Given the discordance between the low frequency of biolo-
gic use despite increased patient satisfaction and less severe
disease while on these medications, we also considered differ-
ences in geographic location as having an impact on biologic
use. Step therapy is a policy developed by insurers that dictates
treatment choices to control costs. Given the high cost of bio-
logic agents, these treatments may not be initially available to a
patient. It was of interest to see if states with Step therapy
legislation might have increased use of biologic agents. Simi-
larly, under the Affordable Care Act, Medicaid expansion
increased eligibility of many individuals to obtain health insur-
ance; how this impacts access to biologic therapy for psoriasis
was not known. Neither Medicaid expansion nor Step therapy
legislation associated with biologic use, opposing our third
hypothesis. Of note, the timeline from the legislative changes
to the timing of the survey was short and should be considered
an area for future research.
Spatial variables (ie, residence in proximity to an NPF Med-
ical Board member, US census divisions and regions) did not
predict biologic use. However, using GIS we were able to
visualize that geographic areas with denser populations, com-
monly where NPF medical board members reside, were asso-
ciated with biologic use in our unadjusted model
(Supplemental Figure 1). GIS has multiple applications of
interest and has previously been used for assessing trends in
medication use and identifying geographic areas of disease
burden.10-14 We were able to identify geographic areas (ie,
counties in Kentucky, Tennessee, North Carolina, South Car-
olina, Georgia, Alabama, Florida, and Texas) where statisti-
cally significant clusters of moderate-to-severe psoriasis
exist. Importantly, a commensurate hot spot of biologic use
was not identified in the majority of these areas. When visua-
lizing the total responses to the NPF 2016 and 2017 Annual
Surveys with GIS, there did not appear to be a lack of outreach
in those areas (Supplemental Figure 2). Reasons for these areas
of clustering will be an area of future research.
There were limitations to this study, primarily its sample
size and the response rate to the annual surveys (2016: 1.4%;
2017: 0.09%). Arguably, with more data, more granular detail
could be used for the GIS analysis. With more data, the hot spot
analyses could potentially identify more counties, allowing for
further downstream investigations to understand local attri-
butes of those populations that might impact therapy and out-
comes. Further, with more data, our chosen geographic
variables may have retained or become significant in our anal-
yses. The entire data set is patient reported and is subject to
response bias. Further, this database represents only those
actively engaged with the NPF, of whom predominantly have
moderate-to-severe disease. It is possible that those well con-
trolled on biologic therapy are underrepresented in the survey
results. We also do not specify between the classes of biologics
and focus on biologics as a broad treatment category. The
variance in specific biologic therapy has been studied in select
populations15,16 and will be an evolving topic for further inves-
tigation. Another limitation is that 84% of respondents identi-
fied as Caucasian; this therefore may overrepresent this ethnic
group in our various analyses.
Conclusion
Here, in an analysis of the 2016 and 2017 NPF Annual Surveys,
despite increases in the number of biologic therapies, the per-
centage of patients with psoriasis on biologic therapy remains
small (<23%). Roughly 69% of respondents reported a BSA
 3%, indicating undertreatment remains a concern in the
United States. Respondents with mild-to-moderate disease
were less likely to receive biologic therapy. Biologic use
resulted in greater satisfaction and less residual disease. Geo-
graphic variation in state legislation as well as state and federal
health insurance did not impact biologic use. However, we
identify a greater burden of moderate-to-severe psoriasis
among respondents in the Southeastern United States and a
lack of commensurate use of biologics in those areas.
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